Price T Rowe Associates Inc Regulus Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 20,393 shares of RGLS stock, worth $32,832. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,393Holding current value
$32,832% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RGLS
# of Institutions
65Shares Held
52.6MCall Options Held
155KPut Options Held
34.2K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$20.7 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.25MShares$10.1 Million0.17% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$8.05 Million1.32% of portfolio
-
Octagon Capital Advisors LP New York, NY4.26MShares$6.86 Million1.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.05MShares$6.52 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $23.6M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...